장영지 (한국과학기술연구원 (KIST)) | 한빛사논문 > 한빛사

한빛사논문

조회144

한국과학기술연구원 (KIST)

Acta Pharm. Sin. B, Available online 2 July 2025 | https://doi.org/10.1016/j.apsb.2025.06.028 Activatable PROTAC nanoassembly for photodynamic PTP1B proteolysis enhances glioblastoma immunotherapy

Yeongji Jang ^{a,b †}, Jiwoong Choi ^{a †}, Byeongmin Park ^a,c, Jung Yeon Park ^c, Jae-Hyeon Lee ^d, Jagyeong Goo ^e, Dongwon Shin^a,c, Sun Hwa Kim^a,c, Yongju Kim ^c,f, Hyun Kyu Song ^b, Jooho Park ^d, Kwangmeyung Kim ^e,g, Yoosoo Yang ^h, Man Kyu Shim^a,i

^aMedicinal Materials Research Center, Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea
^bDepartment of Life Sciences, Korea University, Seoul 02841, Republic of Korea
^cKU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Republic of Korea
^dDepartment of Applied Life Science, BK21 Program, Konkuk University, Chungju 27478, Republic of Korea
^eCollege of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea
^fChemical and Biological Integrative Research Center, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea
^gGradutate Program in Innovative Biomaterials Convergence, Ewha Womans University, 52 Ewhayeodae-gil, Seodaemun-gu, Seoul 03760, Republic of Korea
^hDepartment of Integrative Biotechnology, Sungkyunkwan University, Suwon 16419, Republic of Korea
ⁱDivision of Bio-Medical Science and Technology, KIST School, Korea University of Science and Technology, Seoul 02792, Republic of Korea

^†These authors made equal contributions to this work.
Corresponding authors: Kwangmeyung Kim, Yoosoo Yang, Man Kyu Shim

Abstract

In light of the burgeoning successes of cancer immunotherapy, glioblastoma (GBM) remains refractory due to an immunosuppressive microenvironment originating from its molecular heterogeneity. Thus, identifying promising therapeutic targets for treating GBM and discovering methodologies to effectively regulate them is still a tremendous challenge. Here we describe photodynamic protein tyrosine phosphatase 1B (PTP1B) proteolysis mediated by a proteolysis-targeting chimera (PROTAC) nanoassembly. The PTP1B-targeting PROTAC is conjugated with a photosensitizer via a cathepsin B (Cat B)-cleavable peptide, which spontaneously forms nanoassemblies due to intermolecular π–π stacking interactions. In GBM models, PROTAC nanoassemblies significantly accumulate in the tumor region across the disrupted blood–brain barrier (BBB), triggering a burst release of the photosensitizer and active PROTAC by Cat B-mediated enzymatic cleavage. Upon laser irradiation, photodynamic therapy (PDT) synergizes with PROTAC-mediated PTP1B proteolysis to induce potent immunogenic cell death (ICD) in tumor cells. Subsequently, persistent PTP1B degradation by nanoassemblies in Cat B-overexpressed intratumoral T cells downregulates exhaustion markers, reinvigorating their functionality. These sequential processes of photodynamic PTP1B proteolysis ultimately augment T cell-mediated antitumor immunity as well as protective immunity, completely eradicating the primary GBM and preventing its recurrence. Overall, our findings underscore the therapeutic potential of combining PDT with PROTAC activity for GBM immunotherapy.

논문정보

형식Research article
게재일2025년 07월 (BRIC 등록일 2025-07-03)
연구진국내 연구진
분야 바이오·의료융합 > 바이오센싱 및 나노바이오물질

댓글 작성 로그인

CV 열람하기

연락처 보기